Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,813 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Risk Analysis for Chemotherapy-induced Nausea and Vomiting (CINV) in Patients Receiving FEC100 Treatment.
Hayashi M, Nakazawa K, Hasegawa Y, Horiguchi J, Miura D, Ishikawa T, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Tanino H, Yamada K, Narui K, Kimura K, Akazawa K, Kohno N; JONIE STUDY GROUP. Hayashi M, et al. Among authors: hasegawa y. Anticancer Res. 2019 Aug;39(8):4305-4314. doi: 10.21873/anticanres.13596. Anticancer Res. 2019. PMID: 31366522 Clinical Trial.
Randomized Controlled Trial of Zoledronic Acid plus Chemotherapy versus Chemotherapy Alone as Neoadjuvant Treatment of HER2-Negative Primary Breast Cancer (JONIE Study).
Hasegawa Y, Tanino H, Horiguchi J, Miura D, Ishikawa T, Hayashi M, Takao S, Kim SJ, Yamagami K, Miyashita M, Konishi M, Shigeoka Y, Suzuki M, Taguchi T, Kubota T, Akazawa K, Kohno N; JONIE Study Group. Hasegawa Y, et al. PLoS One. 2015 Dec 3;10(12):e0143643. doi: 10.1371/journal.pone.0143643. eCollection 2015. PLoS One. 2015. PMID: 26633806 Free PMC article. Clinical Trial.
Effects of neoadjuvant chemotherapy with or without zoledronic acid on pathological response: A meta-analysis of randomised trials.
Kroep JR, Charehbili A, Coleman RE, Aft RL, Hasegawa Y, Winter MC, Weilbaecher K, Akazawa K, Hinsley S, Putter H, Liefers GJ, Nortier JWR, Kohno N. Kroep JR, et al. Among authors: hasegawa y. Eur J Cancer. 2016 Feb;54:57-63. doi: 10.1016/j.ejca.2015.10.011. Epub 2015 Dec 23. Eur J Cancer. 2016. PMID: 26722766 Free PMC article.
Effect of denosumab on low bone mineral density in postmenopausal Japanese women receiving adjuvant aromatase inhibitors for non-metastatic breast cancer: 24-month results.
Nakatsukasa K, Koyama H, Ouchi Y, Ono H, Sakaguchi K, Matsuda T, Kato M, Ishikawa T, Yamada K, Yoshimura M, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Niikura N, Hasegawa Y, Miura D, Konishi E, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Nakatsukasa K, et al. Among authors: hasegawa y. Breast Cancer. 2019 Jan;26(1):106-112. doi: 10.1007/s12282-018-0896-y. Epub 2018 Jul 27. Breast Cancer. 2019. PMID: 30054855 Clinical Trial.
A multicenter survey of temporal changes in chemotherapy-induced hair loss in breast cancer patients.
Watanabe T, Yagata H, Saito M, Okada H, Yajima T, Tamai N, Yoshida Y, Takayama T, Imai H, Nozawa K, Sangai T, Yoshimura A, Hasegawa Y, Yamaguchi T, Shimozuma K, Ohashi Y. Watanabe T, et al. Among authors: hasegawa y. PLoS One. 2019 Jan 9;14(1):e0208118. doi: 10.1371/journal.pone.0208118. eCollection 2019. PLoS One. 2019. PMID: 30625139 Free PMC article.
Efficacy of denosumab for restoring normal bone mineral density in women receiving adjuvant aromatase inhibitors for early breast cancer.
Sakaguchi K, Ono H, Nakatsukasa K, Ishikawa T, Hasegawa Y, Takahashi M, Niikura N, Koizumi K, Sakurai T, Shigematsu H, Takahashi S, Taira S, Suzuki M, Narui K, Miura D, Yamada K, Yoshimura M, Shioya H, Konishi E, Isao Y, Imai K, Fujikawa K, Taguchi T; Collaborative Study Group of Scientific Research of the Japanese Breast Cancer Society. Sakaguchi K, et al. Among authors: hasegawa y. Medicine (Baltimore). 2019 Aug;98(32):e16770. doi: 10.1097/MD.0000000000016770. Medicine (Baltimore). 2019. PMID: 31393399 Free PMC article. Clinical Trial.
Efficacy of the eribulin, pertuzumab, and trastuzumab combination therapy for human epidermal growth factor receptor 2-positive advanced or metastatic breast cancer: a multicenter, single arm, phase II study (JBCRG-M03 study).
Yamashita T, Kawaguchi H, Masuda N, Kitada M, Narui K, Hattori M, Yoshinami T, Matsunami N, Yanagihara K, Kawasoe T, Nagashima T, Bando H, Yano H, Hasegawa Y, Nakamura R, Kashiwaba M, Morita S, Ohno S, Toi M. Yamashita T, et al. Among authors: hasegawa y. Invest New Drugs. 2021 Feb;39(1):217-225. doi: 10.1007/s10637-020-00991-6. Epub 2020 Aug 24. Invest New Drugs. 2021. PMID: 32833136 Free PMC article. Clinical Trial.
Prediction of pathological complete response after neoadjuvant chemotherapy in breast cancer by combining magnetic resonance imaging and core needle biopsy.
Narui K, Ishikawa T, Oba MS, Hasegawa Y, Kaise H, Kawate T, Yamada A, Yamada K, Suzuki Y, Niikura N, Kohno N, Kimoto T, Sugae S, Kosaka Y, Miyashita M, Okamura T, Shimizu D, Tanino H, Tanabe M, Morita S, Endo I, Tokuda Y. Narui K, et al. Among authors: hasegawa y. Surg Oncol. 2020 Dec;35:447-452. doi: 10.1016/j.suronc.2020.10.002. Epub 2020 Oct 6. Surg Oncol. 2020. PMID: 33045629
4,813 results